<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394277</url>
  </required_header>
  <id_info>
    <org_study_id>NV18210</org_study_id>
    <nct_id>NCT00394277</nct_id>
  </id_info>
  <brief_title>A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C</brief_title>
  <official_title>Randomized, Multicenter, Double-blinded, Phase IV Study Evaluating the Efficacy (as Measured by Sustained Virological Response) and Safety of 360 μg Induction Dosing of Pegasys® in Combination With Higher Copegus® Doses in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater Than or Equal to 85 kg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 4-arm study will compare the efficacy and safety of PEGASYS induction and maintenance
      dosing, versus standard fixed dosing in combination with Copegus, and the efficacy and safety
      of higher dose versus standard dose Copegus in combination with PEGASYS. Patients with
      chronic hepatitis C (CHC) genotype 1 infection of high viral titer, and baseline body weight
      ≥85 kg, will be randomized to one of 4 groups, to receive one of the following: a) PEGASYS
      180 µg subcutaneously (sc) weekly plus Copegus 1200 mg orally (po) daily; b) PEGASYS 180 µg
      sc weekly plus Copegus 1400-1600 mg po daily; c)PEGASYS 360 µg sc weekly (induction) followed
      by 180 µg sc weekly (maintenance) plus Copegus 1200 mg po daily; or d) PEGASYS 360 µg sc
      weekly (induction) followed by 180 µg sc weekly (maintenance) plus Copegus 1400-1600 mg po
      daily. Following 48 weeks treatment, there will be a 24-week period of treatment-free
      follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size
      is 500+ individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virological Response (SVR)-24 (Scheduled Treatment Period)</measure>
    <time_frame>Week 72</time_frame>
    <description>SVR-24 according to the scheduled treatment period was defined as the percentage of patients with undetectable HCV RNA at 24 weeks after completion of the treatment period (a single last HCV RNA PCR &lt;15 IU/mL measured at or after week 68 (ie, on or after study day 477).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR-24 (Actual Treatment Period)</measure>
    <time_frame>24 weeks after end of treatment</time_frame>
    <description>SVR-24 according to the actual treatment period was defined as the percentage of patients with undetectable HCV RNA at least 20 weeks after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR-12 (Scheduled Treatment Period)</measure>
    <time_frame>12 weeks after end of treatment</time_frame>
    <description>SVR-12 according to the scheduled treatment period was defined as the percentage of patients with undetectable HCV RNA at 12 weeks after the scheduled treatment period (a single last HCV RNA PCR &lt;15 IU/mL measured at or after week 60).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR-12 (Actual Treatment Period)</measure>
    <time_frame>12 weeks after end of treatment</time_frame>
    <description>SVR-12 according to the actual treatment period was defined as the percentage of patients with undetectable HCV RNA at least 12 weeks after the last dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1175</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>PEG-IFN 180 µg + Ribavirin 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-IFN 180 µg + Ribavirin 1400/1600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-IFN 360/180 µg + Ribavirin 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a</intervention_name>
    <description>180 µg sc weekly for 48 weeks</description>
    <arm_group_label>PEG-IFN 180 µg + Ribavirin 1200 mg</arm_group_label>
    <arm_group_label>PEG-IFN 180 µg + Ribavirin 1400/1600 mg</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>1200 mg po daily for 48 weeks</description>
    <arm_group_label>PEG-IFN 180 µg + Ribavirin 1200 mg</arm_group_label>
    <arm_group_label>PEG-IFN 360/180 µg + Ribavirin 1200 mg</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a</intervention_name>
    <description>360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks</description>
    <arm_group_label>PEG-IFN 360/180 µg + Ribavirin 1200 mg</arm_group_label>
    <arm_group_label>PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>1400-1600 mg po daily for 48 weeks</description>
    <arm_group_label>PEG-IFN 180 µg + Ribavirin 1400/1600 mg</arm_group_label>
    <arm_group_label>PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, ≥18 years of age

          -  CHC infection, genotype 1

          -  Hepatitis C virus (HCV) RNA ≥400,000 IU/mL

          -  Baseline body weight ≥85 kg

          -  Liver biopsy (within 24 months of first dose) with results consistent with CHC

        Exclusion Criteria:

          -  Previous treatment with interferon, ribavirin, viramidine, levovirin, HCV polymerase
             or protease inhibitors

          -  Other forms of liver disease, including liver cancer

          -  Human immunodeficiency virus infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-1030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8465</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136-1051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Egg Harbour Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yonkers</city>
        <state>New York</state>
        <zip>10701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604-3200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234-3879</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22906-0013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320-1706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Casper</city>
        <state>Wyoming</state>
        <zip>82609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cheyenne</city>
        <state>Wyoming</state>
        <zip>82001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1030</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caixa</city>
        <zip>18618-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <zip>13083-888</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Juiz de Fora</city>
        <zip>36036-330</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <zip>40110-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Jose Do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>01307</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69288</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <zip>531105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <zip>7654</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kielce</city>
        <zip>25-317</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaloslave</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>11/5</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115446</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117333</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>119881</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>127009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>143420</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <zip>443011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW10 9TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>http://www.roche-trials.com/studyResultGet.action?studyResultNumber=NV18210</url>
    <description>Clinical Study Report Synopsis</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2006</study_first_submitted>
  <study_first_submitted_qc>October 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2006</study_first_posted>
  <results_first_submitted>May 27, 2010</results_first_submitted>
  <results_first_submitted_qc>May 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 5, 2010</results_first_posted>
  <last_update_submitted>July 30, 2010</last_update_submitted>
  <last_update_submitted_qc>July 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Disclosures Group</name_title>
    <organization>Hoffmann-La Roche</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PEG-IFN 180 µg + Ribavirin 1200 mg</title>
          <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
        </group>
        <group group_id="P2">
          <title>PEG-IFN 180 µg + Ribavirin 1400/1600 mg</title>
          <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
        </group>
        <group group_id="P3">
          <title>PEG-IFN 360/180 µg + Ribavirin 1200 mg</title>
          <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
        </group>
        <group group_id="P4">
          <title>PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg</title>
          <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="393"/>
                <participants group_id="P4" count="391"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="273"/>
                <participants group_id="P4" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="125"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEG-IFN 180 µg + Ribavirin 1200 mg</title>
          <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
        </group>
        <group group_id="B2">
          <title>PEG-IFN 180 µg + Ribavirin 1400/1600 mg</title>
          <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
        </group>
        <group group_id="B3">
          <title>PEG-IFN 360/180 µg + Ribavirin 1200 mg</title>
          <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
        </group>
        <group group_id="B4">
          <title>PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg</title>
          <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="195"/>
            <count group_id="B2" value="196"/>
            <count group_id="B3" value="393"/>
            <count group_id="B4" value="391"/>
            <count group_id="B5" value="1175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Intent-to-treat population (all patients treated with at least one dose of either study medication) PEG-IFN 180 µg + Ribavirin 1200 mg: n = 191 PEG-IFN 180 µg + Ribavirin 1400/1600 mg: n = 189 PEG-IFN 360/180 µg + Ribavirin 1200 mg: n = 382 PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg: n = 383</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.1" spread="9.86"/>
                    <measurement group_id="B2" value="45.1" spread="9.50"/>
                    <measurement group_id="B3" value="45.7" spread="9.64"/>
                    <measurement group_id="B4" value="46.0" spread="10.18"/>
                    <measurement group_id="B5" value="45.7" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Intent-to-treat population (all patients treated with at least one dose of either study medication) PEG-IFN 180 µg + Ribavirin 1200 mg: n = 191 PEG-IFN 180 µg + Ribavirin 1400/1600 mg: n = 189 PEG-IFN 360/180 µg + Ribavirin 1200 mg: n = 382 PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg: n = 383</description>
          <units>Patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="292"/>
                    <measurement group_id="B4" value="310"/>
                    <measurement group_id="B5" value="904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virological Response (SVR)-24 (Scheduled Treatment Period)</title>
        <description>SVR-24 according to the scheduled treatment period was defined as the percentage of patients with undetectable HCV RNA at 24 weeks after completion of the treatment period (a single last HCV RNA PCR &lt;15 IU/mL measured at or after week 68 (ie, on or after study day 477).</description>
        <time_frame>Week 72</time_frame>
        <population>Intent-to-treat population (all patients treated with at least one dose of either study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-IFN 180 µg + Ribavirin 1200 mg</title>
            <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
          </group>
          <group group_id="O2">
            <title>PEG-IFN 180 µg + Ribavirin 1400/1600 mg</title>
            <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
          </group>
          <group group_id="O3">
            <title>PEG-IFN 360/180 µg + Ribavirin 1200 mg</title>
            <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
          </group>
          <group group_id="O4">
            <title>PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg</title>
            <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virological Response (SVR)-24 (Scheduled Treatment Period)</title>
          <description>SVR-24 according to the scheduled treatment period was defined as the percentage of patients with undetectable HCV RNA at 24 weeks after completion of the treatment period (a single last HCV RNA PCR &lt;15 IU/mL measured at or after week 68 (ie, on or after study day 477).</description>
          <population>Intent-to-treat population (all patients treated with at least one dose of either study medication)</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="43.5"/>
                    <measurement group_id="O4" value="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This reflects the primary protocol-specified comparison (standard Pegasys induction dosing arms versus pooled Pegasys induction dosing arms). The study was designed to have at least 86% power for testing the null hypothesis of no difference between these two pooled groups, with assumed response rates of 28%, 32%, 36%, and 43% in the four treatment arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.584</p_value>
            <p_value_desc>All secondary comparisons were tested at a two-sided significance level of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value obtained from CMH test, stratified by country and ribavirin dose strata.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.075</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.831</ci_lower_limit>
            <ci_upper_limit>1.391</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR-24 (Actual Treatment Period)</title>
        <description>SVR-24 according to the actual treatment period was defined as the percentage of patients with undetectable HCV RNA at least 20 weeks after the last dose of study drug.</description>
        <time_frame>24 weeks after end of treatment</time_frame>
        <population>Intent-to-treat population (all patients treated with at least one dose of either study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-IFN 180 µg + Ribavirin 1200 mg</title>
            <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
          </group>
          <group group_id="O2">
            <title>PEG-IFN 180 µg + Ribavirin 1400/1600 mg</title>
            <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
          </group>
          <group group_id="O3">
            <title>PEG-IFN 360/180 µg + Ribavirin 1200 mg</title>
            <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
          </group>
          <group group_id="O4">
            <title>PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg</title>
            <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR-24 (Actual Treatment Period)</title>
          <description>SVR-24 according to the actual treatment period was defined as the percentage of patients with undetectable HCV RNA at least 20 weeks after the last dose of study drug.</description>
          <population>Intent-to-treat population (all patients treated with at least one dose of either study medication)</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="43.9"/>
                    <measurement group_id="O3" value="43.5"/>
                    <measurement group_id="O4" value="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>(PEG-IFN 180 µg + Ribavirin 1200 mg and PEG-IFN 180 µg + Ribavirin 1400/1600 mg) vs. (PEG-IFN 360/180 µg + Ribavirin 1200 mg and PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.775</p_value>
            <p_value_desc>All secondary comparisons are tested at a two-sided significance level of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value obtained from CMH test, stratified by country and ribavirin dose strata.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.039</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.803</ci_lower_limit>
            <ci_upper_limit>1.344</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR-12 (Scheduled Treatment Period)</title>
        <description>SVR-12 according to the scheduled treatment period was defined as the percentage of patients with undetectable HCV RNA at 12 weeks after the scheduled treatment period (a single last HCV RNA PCR &lt;15 IU/mL measured at or after week 60).</description>
        <time_frame>12 weeks after end of treatment</time_frame>
        <population>Intent-to-treat population (all patients treated with at least one dose of either study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-IFN 180 µg + Ribavirin 1200 mg</title>
            <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
          </group>
          <group group_id="O2">
            <title>PEG-IFN 180 µg + Ribavirin 1400/1600 mg</title>
            <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
          </group>
          <group group_id="O3">
            <title>PEG-IFN 360/180 µg + Ribavirin 1200 mg</title>
            <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
          </group>
          <group group_id="O4">
            <title>PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg</title>
            <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR-12 (Scheduled Treatment Period)</title>
          <description>SVR-12 according to the scheduled treatment period was defined as the percentage of patients with undetectable HCV RNA at 12 weeks after the scheduled treatment period (a single last HCV RNA PCR &lt;15 IU/mL measured at or after week 60).</description>
          <population>Intent-to-treat population (all patients treated with at least one dose of either study medication)</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3"/>
                    <measurement group_id="O2" value="45.0"/>
                    <measurement group_id="O3" value="44.2"/>
                    <measurement group_id="O4" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>(PEG-IFN 180 µg + Ribavirin 1200 mg and PEG-IFN 180 µg + Ribavirin 1400/1600 mg) vs. (PEG-IFN 360/180 µg + Ribavirin 1200 mg and PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.973</p_value>
            <p_value_desc>All secondary comparisons are tested at a two-sided significance level of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value obtained from CMH test, stratified by country and ribavirin dose strata.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.777</ci_lower_limit>
            <ci_upper_limit>1.299</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR-12 (Actual Treatment Period)</title>
        <description>SVR-12 according to the actual treatment period was defined as the percentage of patients with undetectable HCV RNA at least 12 weeks after the last dose of study drug.</description>
        <time_frame>12 weeks after end of treatment</time_frame>
        <population>Intent-to-treat population (all patients treated with at least one dose of either study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-IFN 180 µg + Ribavirin 1200 mg</title>
            <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
          </group>
          <group group_id="O2">
            <title>PEG-IFN 180 µg + Ribavirin 1400/1600 mg</title>
            <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
          </group>
          <group group_id="O3">
            <title>PEG-IFN 360/180 µg + Ribavirin 1200 mg</title>
            <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
          </group>
          <group group_id="O4">
            <title>PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg</title>
            <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR-12 (Actual Treatment Period)</title>
          <description>SVR-12 according to the actual treatment period was defined as the percentage of patients with undetectable HCV RNA at least 12 weeks after the last dose of study drug.</description>
          <population>Intent-to-treat population (all patients treated with at least one dose of either study medication)</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3"/>
                    <measurement group_id="O2" value="45.5"/>
                    <measurement group_id="O3" value="44.2"/>
                    <measurement group_id="O4" value="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>(PEG-IFN 180 µg + Ribavirin 1200 mg and PEG-IFN 180 µg + Ribavirin 1400/1600 mg) vs. (PEG-IFN 360/180 µg + Ribavirin 1200 mg and PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.951</p_value>
            <p_value_desc>All secondary comparisons are tested at a two-sided significance level of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value obtained from CMH test, stratified by country and ribavirin dose strata.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.780</ci_lower_limit>
            <ci_upper_limit>1.304</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PEG-IFN 180 µg + Ribavirin 1200 mg</title>
          <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
        </group>
        <group group_id="E2">
          <title>PEG-IFN 180 µg + Ribavirin 1400/1600 mg</title>
          <description>PEG-IFN 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
        </group>
        <group group_id="E3">
          <title>PEG-IFN 360/180 µg + Ribavirin 1200 mg</title>
          <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Ribavirin 600 mg administered orally twice daily (total of 1200 mg daily).</description>
        </group>
        <group group_id="E4">
          <title>PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg</title>
          <description>PEG-IFN 360 or 180 µg administered subcutaneously once weekly in abdomen or thigh. Patients with a body weight of 85 kg to &lt;95 kg took 600 mg of ribavirin (3 tablets) in the morning and 800 mg (4 tablets) in the evening, or vice versa; total daily dose was 1400 mg. Patients with a body weight ≥ 95 kg took 800 mg of ribavirin (4 tablets) in the morning and evening; total daily dose was 1600 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Anaemia Haemolytic Autoimmune</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hepatorenal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Bursitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Injection Site Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Intervertebral Discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Lung Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pelvic Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Rectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Postoperative Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Venom Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Fracture Nonunion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hepatic Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pancreatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Tonsil Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Altered State of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hepatic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Metabolic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Peripheral Motor Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Acute Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hostility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolitis Fibrosing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Vena Cava Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="370" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="373" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="104" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="176" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="205" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="184" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="182" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="132" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="111" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="118" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="151" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="168" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="113" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

